NSRX news & sentiment — Nasus Pharma Ltd

MAY 1·Yahoo! Finance CanadaLow

Nasus Pharma to Participate in Upcoming Investor Conferences

Nasus Pharma, a clinical-stage pharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. CFO Eyal Rubin will attend the "Market Movers Investor Summit" and the "D. Boral Capital Global Conference" in New York, engaging in one-on-one meetings with interested investors. The company focuses on developing innovative intranasal products, including NS002, an intranasal epinephrine product for anaphylaxis.

APR 8·Stock Titan

Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)

Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver have collectively reported a 5.2% beneficial ownership stake in Nasus Pharma Ltd (NSRX), totaling 612,913 Ordinary Shares each. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The ownership calculation is based on 11,710,808 shares outstanding as of March 27, 2026.

NOV 20·Benzinga

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer - Nasus Pharma ( AMEX:NSRX )

TEL AVIV, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma", "Nasus" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment ...

$NSRX

Nasus Pharma to Participate in Upcoming Investor Conferences

Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer - Nasus Pharma ( AMEX:NSRX )

News on $NSRX